CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 78,216 enrolled
Drug / intervention
Laboratory Biomarker Analysis +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01696994
NCT01696994N/AActive

Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial

National Cancer Institute (NCI)·interventional·Posted Oct 2, 2012·Updated Apr 29, 2026

In Brief

A clinical study evaluating Laboratory Biomarker Analysis, Screening Questionnaire Administration, and 1 other intervention for Ovarian Carcinoma and Ovarian Germ Cell Tumor. Active but no longer recruiting, targeting 78,216 participants across 1 site.

Detailed Summary

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/AActive
199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
First PostedOct 2, 2012
Enrollment StartNov 16, 1993
Primary CompletionMay 21, 2012
Study CompletionJun 30, 2027
TodayJul 2, 2026
Enrollment to primary: 18.5 yearsPosted 13.8 years ago

Interventions

Laboratory Biomarker Analysisother

Correlative studies

Screening Questionnaire Administrationother

Undergo questionnaire assessments

Ultrasound Imagingprocedure

Undergo TVU